CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood Adv
; 8(7): 1600-1611, 2024 Apr 09.
Article
en En
| MEDLINE
| ID: mdl-37878808
ABSTRACT
ABSTRACT Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Blood Adv
Año:
2024
Tipo del documento:
Article